Supernus and Indivior announce all-stock merger to create CNS-focused drugmaker
read at Endpoints ↗DealPositive
Supernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses.
The new company will be dedicated to developing treatments for central nervous system disorders and will operate under the Supernus name.
Headquarters for the merged entity will be located in Rockville, Maryland, reflecting the focus on CNS disease research.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Update: Supernus, Indivior to merge and form CNS-focused drugmaker”
read at Endpoints ↗79 words · retrieved Aug 3
comments(0)
5-min edit window · permanent after that